<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413515</url>
  </required_header>
  <id_info>
    <org_study_id>17677</org_study_id>
    <nct_id>NCT02413515</nct_id>
  </id_info>
  <brief_title>Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.</brief_title>
  <acronym>ADEPT</acronym>
  <official_title>Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapy: A Prospective, Open-label, Multicenter, Single-arm, 8-week Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate antihypertensive efficacy and tolerability of Nifedipine GITS 60mg treated for 8&#xD;
      weeks in Chinese hypertensive subjects who failed to achieve BP control with the&#xD;
      starting-dose antihypertensive monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: it's a A prospective, open-label, multicenter, single-arm study. After a one-&#xD;
      to two-week screening period, subjects receive Nifedipine GITS 60mg for 8 weeks.&#xD;
&#xD;
      The primary objective is to evaluate the antihypertensive efficacy of 8-week Nifedipine GITS&#xD;
      60mg treatment in Chinese hypertensive subjects who failed to achieve BP control with the&#xD;
      starting-dose antihypertensive mono-therapy.&#xD;
&#xD;
      The secondary objective is to evaluate the tolerability of Nifedipine GITS 60mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2015</start_date>
  <completion_date type="Actual">August 8, 2016</completion_date>
  <primary_completion_date type="Actual">August 8, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with a Mean Sitting Systolic Blood Pressure (&lt;130mmHg for subjects with diabetes and &lt;140mmHg for others) of Nifedipine GITs 60mg</measure>
    <time_frame>At week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Mean Sitting SBP(MSSBP) and Mean Sitting DBP(MSDBP) from baseline at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a Mean Sitting Systolic Blood Pressure Lower than 140mmHg and MSDBP less than 90 mmHg (130 and 80 for diabetis patients) of Nifedipine GITs 60mg</measure>
    <time_frame>At week 2 and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with a MSDBP lower than 90 (80 for diabetis)</measure>
    <time_frame>At week 2 and week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving both a ≥10mmHg</measure>
    <time_frame>At week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the MSSBP target (based on the BP measurements during office visits)</measure>
    <time_frame>up to week 8</time_frame>
    <description>The MSSBP target means : 140 mmHg for others, 130 mmHg for diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the 24-h, daytime (from 06:00 to 22:00), and nighttime (from 22:00 to 06:00) average SBP and DBP assessed by ABPM from baseline at Week 8</measure>
    <time_frame>baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of all treatment-emergent adverse events</measure>
    <time_frame>At week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of drug-related treatment-emergent adverse events</measure>
    <time_frame>at week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat GITS, BAY1040)</intervention_name>
    <description>Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are eligible to be included in the study only if they meet all of the&#xD;
             following criteria:&#xD;
&#xD;
          -  Aged 18 years or older, but less than 65 years;&#xD;
&#xD;
          -  Either male or female&#xD;
&#xD;
          -  BP is uncontrolled after at least 4 weeks of prior antihypertensive mono-therapy (the&#xD;
             dosage of mono-therapy should be the starting dose of an angiotensin receptor blocker&#xD;
             (ARB), angiotensin converting enzyme inhibitor (ACEI), b-blocker (BB), calcium channel&#xD;
             blocker (CCB), or diuretic) both in the beginning and at the end of the screening&#xD;
             period (uncontrolled BP is defined as MSSBP ≥140 and &lt;160mmHg and/or MSDBP ≥ 90 and&#xD;
             &lt;100mmHg, and in the presence of diabetes mellitus: MSSBP ≥130 and &lt;160mmHg and/or&#xD;
             MSDBP ≥80 and &lt;100mmHg);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting any of the following criteria are to be excluded from the study:&#xD;
&#xD;
          -  Known hypersensitivity to nifedipine or to any of the following excipients,&#xD;
             hypromellose, polyethylene oxide, magnesium stearate, sodium chloride, iron oxide red&#xD;
             (E172/C.I.77491), cellulose acetate, polyethylene glycol 3350, hydroxypropyl&#xD;
             cellulose, propylene glycol, titanium dioxide (E171/C.I.77891)&#xD;
&#xD;
          -  Evidence of secondary hypertension such as coarctation of the aorta, pheochromocytoma,&#xD;
             hyperaldosteronism, etc.&#xD;
&#xD;
        Severe gastro-intestinal tract narrowing; gastric banding; kock pouch (ileostomy after&#xD;
        proctocolectomy)&#xD;
&#xD;
          -  Evidence of cardiovascular shock&#xD;
&#xD;
          -  Pregnant, possibly pregnant, planning to become pregnant or lactating women Received&#xD;
             combination (two or more than two drugs combination) therapy or higher dosage (a&#xD;
             higher dosage is defined as a higher dosage than the standard recommended starting&#xD;
             dosage presented in the label of each drug) mono-therapy in the beginning or at the&#xD;
             ending of the screening period.&#xD;
&#xD;
          -  History of cerebrovascular ischemic event (stroke or transient ischemic attack [TIA])&#xD;
             within 6 months&#xD;
&#xD;
          -  History of intracerebral hemorrhage or subarachnoid hemorrhage&#xD;
&#xD;
          -  History of hypertensive retinopathy&#xD;
&#xD;
          -  Any history of heart failure, New York Heart Association (NYHA) classification III or&#xD;
             IV Severe coronary heart disease as manifested by a history of myocardial infarction&#xD;
             or unstable angina in the past 12 months or a history of percutaneous coronary&#xD;
             intervention (PCI) or coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  Clinically significant cardiac valvular disease&#xD;
&#xD;
          -  History of arrhythmia&#xD;
&#xD;
          -  Type 1 diabetes mellitus (DM)&#xD;
&#xD;
          -  Hyperkalemia history: a serum potassium level above the upper limit of normal in the&#xD;
             laboratory range;&#xD;
&#xD;
          -  Liver disease or aspartate transaminase (AST) or alanine transaminase (ALT) levels &gt;3&#xD;
             x upper limit of normal (ULN)&#xD;
&#xD;
          -  Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) of &lt;30&#xD;
             mL/min, or on hemodialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <zip>063000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wudan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shandong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tangshang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

